Overview
Current Evidence is open from the public Pulmonary Hypertension module; no PH password is required. Choose a clinical group, then switch between drug classes and individual drugs. It starts with group 1 in class view. Select a row to inspect its rationale, population and route limits, uncertainty and source-linked reports.
The positions are named editorial categories: favorable, selected-context, mixed, uncertain and unfavorable. They are not clinical effect sizes or a benefit-to-harm ratio. Alphabetical ordering within a category does not rank treatments. Unrated treatments and procedures remain separate; missing appraisal does not mean no harm.
A class can contain differing drug or population findings. Read its named member categories, range and limits rather than assuming a single class effect. Favorable reviewed members excludes unreviewed drugs; missing appraisal does not itself create a mixed result. In group 3, the inhaled treprostinil PH-ILD and PH-COPD results remain different contexts; neither an overall group label nor another route substitutes for the studied population.
This figure summarizes reviewed evidence context for learning. It does not pool incompatible trials, count positive versus harmful reports as a clinical score, infer a patient’s net benefit or change the simulator’s treatment effects. Open the underlying reports and current guidance before drawing a clinical conclusion.